Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

May 3 2010

Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative joint function and motion and reduce postoperative pain. Omeros plans to present these additional data tomorrow in its webcast presentation at the Deutsche Bank Health Care Conference at 2:50 p.m. EDT and, for those not attending, has provided the clinical trial results below.

SOURCE Omeros Corporation

Posted in: Drug Trial News | Medical Procedure News | Medical Condition News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Intermittent fasting shows potential benefits for obesity treatment and brain-gut-microbiome health
The role of RNA splicing in one of the deadliest forms of pancreatic cancer
Using AI to enhance the performance of surgeons: decoding intraoperative surgical activity via accurate machine learning systems
Advancements in understanding and treating breast cancer
Could personalized neoantigen vaccines prevent the recurrence of pancreatic cancer and increase patient survival?
Magnetic soft-robotic chains that can be reconfigured into programmable shapes show potential applications in improving minimally invasive surgery
Does stress increase biological age?
AI in surgery: A double-edged scalpel?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »
You might also like...
Can increasing nut intake prevent frailty in older women?